The Active Ingredient Stands Alone
FDA Law Blog: Biosimilars
JULY 11, 2023
To set the stage for this case, we need to go back to March 2020 , when a new definition of “biological product” threw the world of protein products into a tizzy. That option would not have been available to InvaGen had the FDA instead determined that Somatuline Depot and InvaGen’s product were biological products.”
Let's personalize your content